Review



plko tet on vectors  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Addgene inc plko tet on vectors
    Plko Tet On Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 66 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcw+cas9+blast+vector/pCW-Cas9-Blast+(Plasmid+%2383481)/bio_rxiv__2025__11__28__690983-182-21-25
    Average 94 stars, based on 66 article reviews
    plko tet on vectors - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Transduction:

    Article Title: GiRAFR improves gRNA detection and annotation in single-cell CRISPR screens
    Article Snippet: For lentiviral titration, puromycin (Cayman Chemicals, 13884) resistant colonies were counted through Crystal Violet (Sigma Aldrich, 61135) staining as per the manufacturer’s instructions. .. A549 cells (ATCC) were transduced with a lentivirus encapsulating the pCW-Cas9-Blast vector (Addgene, #83481), followed by selection with 20 μg/mL blasticidin (InvivoGen, 38220000) for 14 days. ..

    Article Title: Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma
    Article Snippet: .. KMS11 or JJN3 cells were transduced with the pCW-Cas9-Blast vector (#83481, Addgene) to establish stable Cas9 + KMS11 and Cas9 + JJN3 cells. ..

    Article Title: GiRAFR improves gRNA detection and annotation in single-cell CRISPR screens.
    Article Snippet: .. A549 cells (ATCC) were transduced with a lentivirus encapsulating the pCW-Cas9-Blast vector (Addgene, #83481), followed by selection with 20 μg/mL blasticidin (InvivoGen, 38220000) for 14 days. ..

    Selection:

    Article Title: GiRAFR improves gRNA detection and annotation in single-cell CRISPR screens
    Article Snippet: For lentiviral titration, puromycin (Cayman Chemicals, 13884) resistant colonies were counted through Crystal Violet (Sigma Aldrich, 61135) staining as per the manufacturer’s instructions. .. A549 cells (ATCC) were transduced with a lentivirus encapsulating the pCW-Cas9-Blast vector (Addgene, #83481), followed by selection with 20 μg/mL blasticidin (InvivoGen, 38220000) for 14 days. ..

    Article Title: GiRAFR improves gRNA detection and annotation in single-cell CRISPR screens.
    Article Snippet: .. A549 cells (ATCC) were transduced with a lentivirus encapsulating the pCW-Cas9-Blast vector (Addgene, #83481), followed by selection with 20 μg/mL blasticidin (InvivoGen, 38220000) for 14 days. ..

    Sequencing:

    Article Title: An engineered hypoxia-response promoter for human umbilical cord-derived mesenchymal stem cell-based therapeutics.
    Article Snippet: .. Specific steps: The CMV promoter sequence of 584 base pairs (bp) was cloned from pcDNA3.1 (+) plasmid (Honorgene, HG-VPI0001); a 358 bp SV40 promoter sequence was cloned from the PGL6 luciferase reporter vector (Beyotime, D2102); a 212 bp Ef1α core promoter sequence was cloned from PX458-EF1α-pSpCas9 (BB) -2 A-GFP plasmid (Addgene, 75232); a 511 bp hPGK1 promoter sequence was cloned from the pCW-Cas9-Blast vector (Addgene, 83481). ..

    Clone Assay:

    Article Title: An engineered hypoxia-response promoter for human umbilical cord-derived mesenchymal stem cell-based therapeutics.
    Article Snippet: .. Specific steps: The CMV promoter sequence of 584 base pairs (bp) was cloned from pcDNA3.1 (+) plasmid (Honorgene, HG-VPI0001); a 358 bp SV40 promoter sequence was cloned from the PGL6 luciferase reporter vector (Beyotime, D2102); a 212 bp Ef1α core promoter sequence was cloned from PX458-EF1α-pSpCas9 (BB) -2 A-GFP plasmid (Addgene, 75232); a 511 bp hPGK1 promoter sequence was cloned from the pCW-Cas9-Blast vector (Addgene, 83481). ..

    Plasmid Preparation:

    Article Title: An engineered hypoxia-response promoter for human umbilical cord-derived mesenchymal stem cell-based therapeutics.
    Article Snippet: .. Specific steps: The CMV promoter sequence of 584 base pairs (bp) was cloned from pcDNA3.1 (+) plasmid (Honorgene, HG-VPI0001); a 358 bp SV40 promoter sequence was cloned from the PGL6 luciferase reporter vector (Beyotime, D2102); a 212 bp Ef1α core promoter sequence was cloned from PX458-EF1α-pSpCas9 (BB) -2 A-GFP plasmid (Addgene, 75232); a 511 bp hPGK1 promoter sequence was cloned from the pCW-Cas9-Blast vector (Addgene, 83481). ..

    Article Title: Base-excision repair pathway regulates transcription-replication conflicts in pancreatic ductal adenocarcinoma.
    Article Snippet: The KRAS-G12D cDNA were retrieved from pHAGE-KRAS-G12D vector by double digesting with Nhe-I and Bam-H1 followed by gel purification. .. The purified KRAS-G12D fragment was then ligated with mainframe of pCW-Cas9-Blast vector (addgene 83481) with Cas9 genes being replaced with KrasG12D. ..

    Article Title: Base Excision Repair Pathway Regulates Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma
    Article Snippet: The KRAS-G12D cDNA were retrieved from pHAGE-KRAS-G12D vector by double digesting with Nhe-I and Bam-H1 followed by gel purification. .. The purified KRAS-G12D fragment was then ligated with mainframe of pCW-Cas9-Blast vector (addgene 83481) with Cas9 genes being replaced with KrasG12D. ..

    Article Title: Use of MYOG gene as target in preparation of drug for treating cardiomyocyte apoptosis-associated cardiovascular disease
    Article Snippet: .. 1.1 Construction of a lentiviral expression vector: MYOG cDNA and a puromycin resistance gene were subcloned into a pCW-Cas9-Blast vector (Addgene, 83481) by a conventional molecular cloning method to replace the Cas9 and Blast genes in the original vector to obtain pCW-MYOG. ..

    Article Title: ZBTB18 restricts chromatin accessibility and prevents transcriptional adaptations that drive metastasis.
    Article Snippet: .. For the inducible Tgfbr2 construct, Tgfbr2 was cut out from the pCMV-mTgfbr2-GFPSpark plasmid (Sino Biological) with the Nhe I and Bam HI restriction enzymes and then subcloned into the Xba I and Bam HI restriction sites of the pCW-Cas9-Blast vector (a gift from M. Babu; Addgene, plasmid no. 83481). .. Packaging of the vectors described above was obtained by cotransfecting 293FT cells with 1.3 μg of transfer vector and 0.67 μg of pCAG-kGP1-1R, 0.22 μg of pCAG-VSV-G, and 0.22 μg of pCAG4-RTR2 or 1 μg of pCMV-dR8.9 and 1 μg of pCAG-VSV-G helper plasmids using TransIT-293 reagent (Mirus) in Opti-MEM I (Thermo Fisher Scientific).

    Luciferase:

    Article Title: An engineered hypoxia-response promoter for human umbilical cord-derived mesenchymal stem cell-based therapeutics.
    Article Snippet: .. Specific steps: The CMV promoter sequence of 584 base pairs (bp) was cloned from pcDNA3.1 (+) plasmid (Honorgene, HG-VPI0001); a 358 bp SV40 promoter sequence was cloned from the PGL6 luciferase reporter vector (Beyotime, D2102); a 212 bp Ef1α core promoter sequence was cloned from PX458-EF1α-pSpCas9 (BB) -2 A-GFP plasmid (Addgene, 75232); a 511 bp hPGK1 promoter sequence was cloned from the pCW-Cas9-Blast vector (Addgene, 83481). ..

    Purification:

    Article Title: Base-excision repair pathway regulates transcription-replication conflicts in pancreatic ductal adenocarcinoma.
    Article Snippet: The KRAS-G12D cDNA were retrieved from pHAGE-KRAS-G12D vector by double digesting with Nhe-I and Bam-H1 followed by gel purification. .. The purified KRAS-G12D fragment was then ligated with mainframe of pCW-Cas9-Blast vector (addgene 83481) with Cas9 genes being replaced with KrasG12D. ..

    Article Title: Base Excision Repair Pathway Regulates Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma
    Article Snippet: The KRAS-G12D cDNA were retrieved from pHAGE-KRAS-G12D vector by double digesting with Nhe-I and Bam-H1 followed by gel purification. .. The purified KRAS-G12D fragment was then ligated with mainframe of pCW-Cas9-Blast vector (addgene 83481) with Cas9 genes being replaced with KrasG12D. ..

    Expressing:

    Article Title: Use of MYOG gene as target in preparation of drug for treating cardiomyocyte apoptosis-associated cardiovascular disease
    Article Snippet: .. 1.1 Construction of a lentiviral expression vector: MYOG cDNA and a puromycin resistance gene were subcloned into a pCW-Cas9-Blast vector (Addgene, 83481) by a conventional molecular cloning method to replace the Cas9 and Blast genes in the original vector to obtain pCW-MYOG. ..

    Molecular Cloning:

    Article Title: Use of MYOG gene as target in preparation of drug for treating cardiomyocyte apoptosis-associated cardiovascular disease
    Article Snippet: .. 1.1 Construction of a lentiviral expression vector: MYOG cDNA and a puromycin resistance gene were subcloned into a pCW-Cas9-Blast vector (Addgene, 83481) by a conventional molecular cloning method to replace the Cas9 and Blast genes in the original vector to obtain pCW-MYOG. ..

    Construct:

    Article Title: ZBTB18 restricts chromatin accessibility and prevents transcriptional adaptations that drive metastasis.
    Article Snippet: .. For the inducible Tgfbr2 construct, Tgfbr2 was cut out from the pCMV-mTgfbr2-GFPSpark plasmid (Sino Biological) with the Nhe I and Bam HI restriction enzymes and then subcloned into the Xba I and Bam HI restriction sites of the pCW-Cas9-Blast vector (a gift from M. Babu; Addgene, plasmid no. 83481). .. Packaging of the vectors described above was obtained by cotransfecting 293FT cells with 1.3 μg of transfer vector and 0.67 μg of pCAG-kGP1-1R, 0.22 μg of pCAG-VSV-G, and 0.22 μg of pCAG4-RTR2 or 1 μg of pCMV-dR8.9 and 1 μg of pCAG-VSV-G helper plasmids using TransIT-293 reagent (Mirus) in Opti-MEM I (Thermo Fisher Scientific).



    Similar Products

    94
    Addgene inc plko tet on vectors
    Plko Tet On Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcw+cas9+blast+vector/pCW-Cas9-Blast+(Plasmid+%2383481)/bio_rxiv__2025__11__28__690983-182-21-25
    Average 94 stars, based on 1 article reviews
    plko tet on vectors - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Addgene inc lentiviral expression vector pcw cas9 blast
    Lentiviral Expression Vector Pcw Cas9 Blast, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcw+cas9+blast+vector/pCW-Cas9-Blast+(Plasmid+%2383481)/pmc12514574-275-8-17
    Average 94 stars, based on 1 article reviews
    lentiviral expression vector pcw cas9 blast - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Addgene inc lentiviral expression vector pcw cas9blast
    Lentiviral Expression Vector Pcw Cas9blast, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcw+cas9+blast+vector/pCW-Cas9-Blast+(Plasmid+%2383481)/pm40914247-197-8-17
    Average 94 stars, based on 1 article reviews
    lentiviral expression vector pcw cas9blast - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Addgene inc pcw cas9 blast vector
    Pcw Cas9 Blast Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcw+cas9+blast+vector/pCW-Cas9-Blast+(Plasmid+%2383481)/pm40597956-66-62-64
    Average 94 stars, based on 1 article reviews
    pcw cas9 blast vector - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Addgene inc inducible cas9 vector
    FBXO45 deficiency sensitizes BCL to MAPK pathway inhibition in vitro and in vivo . A, FBXO45 WT or <t>CRISPR-Cas9–mediated</t> FBXO45 KO iBJAB (“i”, doxycycline-inducible Cas9 expression) cells were treated with cycloheximide (CHX), and WCE was analyzed by WB with indicated antibodies. B, FBXO45 WT and KO iBJAB cells were treated with trametinib as indicated, and WCEs were analyzed by WB with the indicated antibodies. C, FBXO45 WT and KO iBJAB cells were xenografted in NSG mice and treated with trametinib as detailed in the “Methods” section. Tumor volumes of mice treated with trametinib for both FBXO45 WT and KO ( n = 6 each) were individually measured every 3 days. Experiments were performed in triplicate. D, In vivo imaging studies at day 25 show decreased tumor sizes in response to trametinib treatment in FBXO45 KO xenografts. At the end of the study (day 25), tumors were surgically removed for imaging analysis, as shown in the right panel. E, The top panel shows a schematic illustration of the experimental plan to evaluate trametinib treatment on xenograft tumors originated by FL518-CBG luciferase cells. The bottom panel shows representative BLI at days 1,6, 8 and 13. F, Relative bioluminescence (RLU or relative luminescence units) for each group of mice was measured and plotted for day 13. Two-tailed Mann–Whitney unpaired Student’s t test was used for analysis (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001). G, Kaplan–Meier survival curves of NS shRNA and FBXO45 shRNA expressing FL518-derived lymphoma xenografts in SCID-BEIGE mice. Log-rank (Mantel–Cox) test was used for analysis. WB, Western blotting; WCE, whole cell extract. Dox, doxycycline; ns, not significant.
    Inducible Cas9 Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcw+cas9+blast+vector/pCW-Cas9-Blast+(Plasmid+%2383481)/pmc11962402-394-10-14
    Average 94 stars, based on 1 article reviews
    inducible cas9 vector - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Addgene inc plko based sgrna vector
    Figure 1 Genome-wide CRISPR/Cas9 screening identifies genes involved in NKp44-mediated specific killing of tumor cells by KHYG-1 cells. (A) Genome-wide CRISPR/Cas9 screening design. HCT-116 Cas9+ cells were transduced with the knockout <t>sgRNA</t> Brunello library. Collection of mutant cells was subjected to lysis by WT KHYG-1 or NKp44-deficient KHYG-1 in the presence of α-NKp44 mAb or not (Round 1). Mutant cells that survived lysis by KHYG-1 were subjected to a second round (Round 2) of co-culture with WT KHYG-1 (condition 1), in the presence of α-NKp44 mAb (condition 2) or with NKp44-deficient KHYG-1 (condition 3). The abundance of sgRNA in the collection, in the surviving cells in Round 1 and in the surviving cells in Round 2 were determined by sequencing (see Material and methods). (B) Venn diagram of hits obtained with KHYG-1 co-culture (condition 1, see online supplemental table 1), KHYG-1+αNKp44mAb (condition 2, see online supplemental table 2) and NKp44- deficient KHYG-1 cells (condition 3, see online supplemental table 3). (B) Scatter plot showing the ranking of hits enriched in the NKp44-dependent killing of tumor cells by KHYG-1 cells by MAGeCK score and false discovery rate (see online supplemental table 4). FDR, false discovery rate; mAb, monoclonal antibody; sgRNA, single guide RNA; WT, wild-type.
    Plko Based Sgrna Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcw+cas9+blast+vector/pCW-Cas9-Blast+(Plasmid+%2383481)/pm40164474-60-17-24
    Average 94 stars, based on 1 article reviews
    plko based sgrna vector - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Addgene inc pcw cas9 tet on vector
    Figure 1 Genome-wide CRISPR/Cas9 screening identifies genes involved in NKp44-mediated specific killing of tumor cells by KHYG-1 cells. (A) Genome-wide CRISPR/Cas9 screening design. HCT-116 Cas9+ cells were transduced with the knockout <t>sgRNA</t> Brunello library. Collection of mutant cells was subjected to lysis by WT KHYG-1 or NKp44-deficient KHYG-1 in the presence of α-NKp44 mAb or not (Round 1). Mutant cells that survived lysis by KHYG-1 were subjected to a second round (Round 2) of co-culture with WT KHYG-1 (condition 1), in the presence of α-NKp44 mAb (condition 2) or with NKp44-deficient KHYG-1 (condition 3). The abundance of sgRNA in the collection, in the surviving cells in Round 1 and in the surviving cells in Round 2 were determined by sequencing (see Material and methods). (B) Venn diagram of hits obtained with KHYG-1 co-culture (condition 1, see online supplemental table 1), KHYG-1+αNKp44mAb (condition 2, see online supplemental table 2) and NKp44- deficient KHYG-1 cells (condition 3, see online supplemental table 3). (B) Scatter plot showing the ranking of hits enriched in the NKp44-dependent killing of tumor cells by KHYG-1 cells by MAGeCK score and false discovery rate (see online supplemental table 4). FDR, false discovery rate; mAb, monoclonal antibody; sgRNA, single guide RNA; WT, wild-type.
    Pcw Cas9 Tet On Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcw+cas9+blast+vector/pCW-Cas9-Blast+(Plasmid+%2383481)/pm39983719-542-10-13
    Average 94 stars, based on 1 article reviews
    pcw cas9 tet on vector - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Addgene inc cumate inducible lentiviral vectors
    Figure 1 Genome-wide CRISPR/Cas9 screening identifies genes involved in NKp44-mediated specific killing of tumor cells by KHYG-1 cells. (A) Genome-wide CRISPR/Cas9 screening design. HCT-116 Cas9+ cells were transduced with the knockout <t>sgRNA</t> Brunello library. Collection of mutant cells was subjected to lysis by WT KHYG-1 or NKp44-deficient KHYG-1 in the presence of α-NKp44 mAb or not (Round 1). Mutant cells that survived lysis by KHYG-1 were subjected to a second round (Round 2) of co-culture with WT KHYG-1 (condition 1), in the presence of α-NKp44 mAb (condition 2) or with NKp44-deficient KHYG-1 (condition 3). The abundance of sgRNA in the collection, in the surviving cells in Round 1 and in the surviving cells in Round 2 were determined by sequencing (see Material and methods). (B) Venn diagram of hits obtained with KHYG-1 co-culture (condition 1, see online supplemental table 1), KHYG-1+αNKp44mAb (condition 2, see online supplemental table 2) and NKp44- deficient KHYG-1 cells (condition 3, see online supplemental table 3). (B) Scatter plot showing the ranking of hits enriched in the NKp44-dependent killing of tumor cells by KHYG-1 cells by MAGeCK score and false discovery rate (see online supplemental table 4). FDR, false discovery rate; mAb, monoclonal antibody; sgRNA, single guide RNA; WT, wild-type.
    Cumate Inducible Lentiviral Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pcw+cas9+blast+vector/pCW-Cas9-Blast+(Plasmid+%2383481)/pm39300211-218-1-8
    Average 94 stars, based on 1 article reviews
    cumate inducible lentiviral vectors - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    FBXO45 deficiency sensitizes BCL to MAPK pathway inhibition in vitro and in vivo . A, FBXO45 WT or CRISPR-Cas9–mediated FBXO45 KO iBJAB (“i”, doxycycline-inducible Cas9 expression) cells were treated with cycloheximide (CHX), and WCE was analyzed by WB with indicated antibodies. B, FBXO45 WT and KO iBJAB cells were treated with trametinib as indicated, and WCEs were analyzed by WB with the indicated antibodies. C, FBXO45 WT and KO iBJAB cells were xenografted in NSG mice and treated with trametinib as detailed in the “Methods” section. Tumor volumes of mice treated with trametinib for both FBXO45 WT and KO ( n = 6 each) were individually measured every 3 days. Experiments were performed in triplicate. D, In vivo imaging studies at day 25 show decreased tumor sizes in response to trametinib treatment in FBXO45 KO xenografts. At the end of the study (day 25), tumors were surgically removed for imaging analysis, as shown in the right panel. E, The top panel shows a schematic illustration of the experimental plan to evaluate trametinib treatment on xenograft tumors originated by FL518-CBG luciferase cells. The bottom panel shows representative BLI at days 1,6, 8 and 13. F, Relative bioluminescence (RLU or relative luminescence units) for each group of mice was measured and plotted for day 13. Two-tailed Mann–Whitney unpaired Student’s t test was used for analysis (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001). G, Kaplan–Meier survival curves of NS shRNA and FBXO45 shRNA expressing FL518-derived lymphoma xenografts in SCID-BEIGE mice. Log-rank (Mantel–Cox) test was used for analysis. WB, Western blotting; WCE, whole cell extract. Dox, doxycycline; ns, not significant.

    Journal: Cancer Discovery

    Article Title: The FBXO45–GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis

    doi: 10.1158/2159-8290.CD-24-0442

    Figure Lengend Snippet: FBXO45 deficiency sensitizes BCL to MAPK pathway inhibition in vitro and in vivo . A, FBXO45 WT or CRISPR-Cas9–mediated FBXO45 KO iBJAB (“i”, doxycycline-inducible Cas9 expression) cells were treated with cycloheximide (CHX), and WCE was analyzed by WB with indicated antibodies. B, FBXO45 WT and KO iBJAB cells were treated with trametinib as indicated, and WCEs were analyzed by WB with the indicated antibodies. C, FBXO45 WT and KO iBJAB cells were xenografted in NSG mice and treated with trametinib as detailed in the “Methods” section. Tumor volumes of mice treated with trametinib for both FBXO45 WT and KO ( n = 6 each) were individually measured every 3 days. Experiments were performed in triplicate. D, In vivo imaging studies at day 25 show decreased tumor sizes in response to trametinib treatment in FBXO45 KO xenografts. At the end of the study (day 25), tumors were surgically removed for imaging analysis, as shown in the right panel. E, The top panel shows a schematic illustration of the experimental plan to evaluate trametinib treatment on xenograft tumors originated by FL518-CBG luciferase cells. The bottom panel shows representative BLI at days 1,6, 8 and 13. F, Relative bioluminescence (RLU or relative luminescence units) for each group of mice was measured and plotted for day 13. Two-tailed Mann–Whitney unpaired Student’s t test was used for analysis (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001). G, Kaplan–Meier survival curves of NS shRNA and FBXO45 shRNA expressing FL518-derived lymphoma xenografts in SCID-BEIGE mice. Log-rank (Mantel–Cox) test was used for analysis. WB, Western blotting; WCE, whole cell extract. Dox, doxycycline; ns, not significant.

    Article Snippet: Lentiviral packaging plasmids pMD2.G (RRID: Addgene_12259), psPAX2 (RRID: Addgene_12260), and inducible Cas9 vector (RRID: Addgene_83481) were obtained from Addgene.

    Techniques: Inhibition, In Vitro, In Vivo, CRISPR, Expressing, In Vivo Imaging, Imaging, Luciferase, Two Tailed Test, MANN-WHITNEY, shRNA, Derivative Assay, Western Blot

    Figure 1 Genome-wide CRISPR/Cas9 screening identifies genes involved in NKp44-mediated specific killing of tumor cells by KHYG-1 cells. (A) Genome-wide CRISPR/Cas9 screening design. HCT-116 Cas9+ cells were transduced with the knockout sgRNA Brunello library. Collection of mutant cells was subjected to lysis by WT KHYG-1 or NKp44-deficient KHYG-1 in the presence of α-NKp44 mAb or not (Round 1). Mutant cells that survived lysis by KHYG-1 were subjected to a second round (Round 2) of co-culture with WT KHYG-1 (condition 1), in the presence of α-NKp44 mAb (condition 2) or with NKp44-deficient KHYG-1 (condition 3). The abundance of sgRNA in the collection, in the surviving cells in Round 1 and in the surviving cells in Round 2 were determined by sequencing (see Material and methods). (B) Venn diagram of hits obtained with KHYG-1 co-culture (condition 1, see online supplemental table 1), KHYG-1+αNKp44mAb (condition 2, see online supplemental table 2) and NKp44- deficient KHYG-1 cells (condition 3, see online supplemental table 3). (B) Scatter plot showing the ranking of hits enriched in the NKp44-dependent killing of tumor cells by KHYG-1 cells by MAGeCK score and false discovery rate (see online supplemental table 4). FDR, false discovery rate; mAb, monoclonal antibody; sgRNA, single guide RNA; WT, wild-type.

    Journal: Journal for immunotherapy of cancer

    Article Title: Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing.

    doi: 10.1136/jitc-2024-010699

    Figure Lengend Snippet: Figure 1 Genome-wide CRISPR/Cas9 screening identifies genes involved in NKp44-mediated specific killing of tumor cells by KHYG-1 cells. (A) Genome-wide CRISPR/Cas9 screening design. HCT-116 Cas9+ cells were transduced with the knockout sgRNA Brunello library. Collection of mutant cells was subjected to lysis by WT KHYG-1 or NKp44-deficient KHYG-1 in the presence of α-NKp44 mAb or not (Round 1). Mutant cells that survived lysis by KHYG-1 were subjected to a second round (Round 2) of co-culture with WT KHYG-1 (condition 1), in the presence of α-NKp44 mAb (condition 2) or with NKp44-deficient KHYG-1 (condition 3). The abundance of sgRNA in the collection, in the surviving cells in Round 1 and in the surviving cells in Round 2 were determined by sequencing (see Material and methods). (B) Venn diagram of hits obtained with KHYG-1 co-culture (condition 1, see online supplemental table 1), KHYG-1+αNKp44mAb (condition 2, see online supplemental table 2) and NKp44- deficient KHYG-1 cells (condition 3, see online supplemental table 3). (B) Scatter plot showing the ranking of hits enriched in the NKp44-dependent killing of tumor cells by KHYG-1 cells by MAGeCK score and false discovery rate (see online supplemental table 4). FDR, false discovery rate; mAb, monoclonal antibody; sgRNA, single guide RNA; WT, wild-type.

    Article Snippet: The cells were then maintained at 37°C in an atmosphere containing 5% CO2. pCW- Cas9 blast and pLKO- based sgRNA vector were purchased from Addgene (plasmid #83481 and #52628, respectively).

    Techniques: Genome Wide, CRISPR, Transduction, Knock-Out, Mutagenesis, Lysis, Co-Culture Assay, Sequencing